Recent Updates
Recently added Catalysts
RVTY Positive Sentiment

Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes

Thursday, September 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Revvity, Inc. has launched the GSP® T1D 3plex kit, an automated solution for detecting autoantibodies related to type 1 diabetes (T1D). This CE-IVDR-certified kit aims to facilitate population-wide screening, allowing for early identification of children at risk before symptoms manifest. The initiative addresses a significant public health challenge associated with T1D.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of a new automated detection solution for T1D.
  • CE-IVDR certification enhances credibility and market acceptance.
  • Potential for early identification of at-risk children.

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear. A critical public health challenge, T1D is often only identified after significant beta-cell damage has occurred, presenting first as a life-threatening diabetic k

Frequently Asked Questions

What is the GSP® T1D 3plex kit?

It is an automated, CE-IVDR-certified solution for detecting autoantibodies related to type 1 diabetes.

How does the T1D kit help in public health?

It enables early identification of children at risk for type 1 diabetes, addressing a critical health challenge.

What certification does the T1D detection kit have?

The kit is CE-IVDR certified, ensuring its compliance with European regulations.

Why is early detection of T1D important?

Early detection can prevent significant beta-cell damage and improve health outcomes.

ShareAdd on Google
Tags: RVTY Viatris Investor Conferences Healthcare Revvity T1D autoantibody detection CE-IVDR screening
Last updated: Sep 24, 2026

Biotech snapshot

Cash runway
$1023M liquidity · $0M/mo burn
Low dilution risk